Condition
Sickle Cell Nephropathy
Total Trials
6
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Unknown2
Recruiting2
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07246265Not ApplicableRecruiting
Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
NCT04335721Phase 1Terminated
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
NCT06065852Recruiting
National Registry of Rare Kidney Diseases
NCT01732718Phase 2Completed
Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
NCT03680547UnknownPrimary
Nephropathy in Patients With Sickle Cell Disease
NCT01891292Not ApplicableUnknown
Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy
Showing all 6 trials